Oncolytics Biotech (NASDAQ:ONCY) Stock Rating Lowered by Leede Financial

Oncolytics Biotech (NASDAQ:ONCY) was downgraded by equities research analysts at Leede Financial from a “strong-buy” rating to a “moderate buy” rating in a research report issued on Wednesday,Zacks.com reports.

Separately, HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of Oncolytics Biotech in a research note on Thursday.

Oncolytics Biotech Stock Down 3.0 %

ONCY opened at $0.98 on Wednesday. The stock has a market cap of $75.53 million, a price-to-earnings ratio of -3.63 and a beta of 1.69. Oncolytics Biotech has a twelve month low of $0.84 and a twelve month high of $1.75. The company’s 50-day moving average price is $1.09 and its two-hundred day moving average price is $1.06.

Institutional Trading of Oncolytics Biotech

A hedge fund recently bought a new stake in Oncolytics Biotech stock. Virtu Financial LLC purchased a new stake in Oncolytics Biotech Inc. (NASDAQ:ONCY) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 51,889 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 0.07% of Oncolytics Biotech as of its most recent SEC filing. Hedge funds and other institutional investors own 6.82% of the company’s stock.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.